OK, that may be one good thing they might have going for them. But taking the broadest view of the company that I've observed, there are just too many negatives. Their drugs are either pre-clinical or in Phase I/II. They keep touting annamycin as their lead candidate, but that's not a cancer drug. Look at the pipeline - https://www.moleculin.com/pipeline/ . You know that very few drugs make it from those stages of development to FDA approval. And there are probably thousands of other companies, Big Pharma included, targeting those same indications.
They had a CC today starting at 4:30 Eastern. Maybe you can find a link to it on their website if you're interested. The stock is off from a $1.74 closing price to $1.51 AH as I write. You can find some relevant comments on the iHub message board for MBRX if you're inclined to do so.
News 
Market Data 
Discover 
